Organogenesis Holdings Inc.ORGOEarnings & Financial Report
Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.
Revenue
$101.0M
Gross Profit
N/A
Operating Profit
$-12.6M
Net Profit
$-9.4M
Gross Margin
N/A
Operating Margin
-12.5%
Net Margin
-9.3%
YoY Growth
-22.4%
EPS
$-0.10
Organogenesis Holdings Inc. Q2 FY2025 Financial Summary
Organogenesis Holdings Inc. reported revenue of $101.0M (down 22.4% YoY) for Q2 FY2025, with a net profit of $-9.4M (up 44.9% YoY) (-9.3% margin).
Key Financial Metrics
| Total Revenue | $101.0M |
|---|---|
| Net Profit | $-9.4M |
| Gross Margin | N/A |
| Operating Margin | -12.5% |
| Report Period | Q2 FY2025 |
Organogenesis Holdings Inc. Annual Revenue by Year
Organogenesis Holdings Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $564.2M).
| Year | Annual Revenue |
|---|---|
| 2025 | $564.2M |
| 2024 | $482.0M |
| 2023 | $433.1M |
| 2022 | $450.9M |
Organogenesis Holdings Inc. Quarterly Revenue & Net Profit History
Organogenesis Holdings Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $37.2M | -57.1% | N/A | N/A |
| Q4 FY2025 | $225.6M | +78.1% | $43.7M | 19.4% |
| Q3 FY2025 | $150.9M | +31.0% | $21.6M | 14.3% |
| Q2 FY2025 | $101.0M | -22.4% | $-9.4M | -9.3% |
| Q1 FY2025 | $86.7M | -21.2% | $-18.8M | -21.7% |
| Q4 FY2024 | $126.7M | +27.1% | $7.7M | 6.1% |
| Q3 FY2024 | $115.2M | +6.1% | $12.3M | 10.7% |
| Q2 FY2024 | $130.2M | +11.0% | $-17.0M | -13.1% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $130.2M | $115.2M | $126.7M | $86.7M | $101.0M | $150.9M | $225.6M | $37.2M |
| YoY Growth | 11.0% | 6.1% | 27.1% | -21.2% | -22.4% | 31.0% | 78.1% | -57.1% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $443.2M | $446.3M | $497.9M | $467.4M | $461.1M | $509.8M | $598.7M | $520.0M |
| Liabilities | $179.7M | $167.7M | $112.6M | $99.3M | $99.9M | $123.8M | $164.8M | $138.6M |
| Equity | $263.5M | $278.5M | $262.9M | $242.9M | $233.2M | $255.1M | $300.1M | N/A |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $4.7M | $8.7M | $10.9M | $-19.9M | $-32.9M | $3.1M | $39.4M |